Anis A H, Guh D, Hogg R S, Wang X H, Yip B, Craib K J, O'Shaughnessy M V, Schechter M T, Montaner J S
British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada.
Pharmacoeconomics. 2000 Oct;18(4):393-404. doi: 10.2165/00019053-200018040-00007.
To estimate survival, the number of life-years gained and cost effectiveness of antiretroviral therapy (ART) regimens, denoted as ERA-I [zidovudine + (didanosine or zalcitabine)]; ERA-II [stavudine + (didanosine or zalcitabine) or lamivudine + (zidovudine or didanosine or zalcitabine or stavudine)]; and ERA-III [2 nucleoside reverse transcriptase inhibitors + (1 protease inhibitor or 1 non-nucleoside reverse transcriptase inhibitor)].
Modelling of drug cost, cost of opportunistic diseases and survival of HIV positive men and women in the province of British Columbia who were first prescribed any ART between October 1992 and June 1996. A 'reference cohort' was modelled upon individuals in a longitudinal cohort of homosexual men followed since 1982. PERSPECTIVE AND SETTING: Third-party payer perspective in British Columbia, Canada.
All HIV-positive men and women aged > or =18 years with CD4+ counts < or =350 cells/microL who were enrolled in the province-wide drug treatment programme.
Annual costs, survival and cost-effectiveness ratios of successive ART regimens.
Total costs [1997 Canadian dollars ($Can)] at 12 months under ERA-I, -II and -III were $Can4897, $Can6620 and $Can 11 914, respectively. Survival at 12 months under ERA-I, -II and -III was 89.6%, 91.0% and 97.6%, respectively. The annual incremental cost (estimated by the total incremental cost at 12 months) between ERA-II and ERA-I was $Can1723. The incremental cost-effectiveness ratios between ERA-III and ERA-I, and between ERA-III and ERA-II were $Can58 806 and $Can46 971 per life-year gained, respectively.
We found the cost effectiveness of ERA-III ART regimens well within the range of currently funded therapies for the treatment of other chronic diseases.
评估抗逆转录病毒治疗（ART）方案的生存率、获得的生命年数及成本效益，这些方案分别为ERA - I[齐多夫定 +（去羟肌苷或扎西他滨）]；ERA - II[司他夫定 +（去羟肌苷或扎西他滨）或拉米夫定 +（齐多夫定或去羟肌苷或扎西他滨或司他夫定）]；以及ERA - III[2种核苷类逆转录酶抑制剂 +（1种蛋白酶抑制剂或1种非核苷类逆转录酶抑制剂）]。
对1992年10月至1996年6月期间首次接受任何抗逆转录病毒治疗的不列颠哥伦比亚省HIV阳性男性和女性的药物成本、机会性疾病成本及生存率进行建模。“参考队列”基于自1982年起随访的同性恋男性纵向队列中的个体构建。视角与背景：加拿大不列颠哥伦比亚省第三方支付方视角。
所有年龄≥18岁、CD4 + 细胞计数≤350个/微升且参加全省药物治疗项目的HIV阳性男性和女性。
连续抗逆转录病毒治疗方案的年度成本、生存率及成本效益比。
ERA - I、ERA - II和ERA - III方案在12个月时的总成本（1997年加拿大元）分别为4897加元、6620加元和11914加元。ERA - I、ERA - II和ERA - III方案在12个月时的生存率分别为89.6%、91.0%和97.6%。ERA - II与ERA - I之间的年度增量成本（按12个月时的总增量成本估算）为1723加元。ERA - III与ERA - I之间以及ERA - III与ERA - II之间每获得一个生命年的增量成本效益比分别为58806加元和46971加元。
我们发现ERA - III抗逆转录病毒治疗方案的成本效益完全在目前用于治疗其他慢性疾病的已获资助疗法范围内。
